CUPR

SINGAPORE, May 29, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it completed a reverse stock split on May 27, 2026, and requested  a hearing before the Nasdaq Hearings Panel (the "Panel"), in response to a staff determination letter (the "Letter") received on May 27, 2026, from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq"). The Letter notified the Company that, due to the Company's failure to regain compliance with a minim

SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced that it plans to implement a 1-for-8 share consolidation of its Class A ordinary shares ("Class A Ordinary Shares") and Class B ordinary shares ("Class B Ordinary Shares") (the "Share Consolidation"), effective on or around May 27, 2026. Beginning with the opening of trading on or around May 27, 2026, the Company's Class A Ordinary Shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capi

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K/A - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

20-F - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

3 - Cuprina Holdings (Cayman) LTD (0001995704) (Issuer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Regulatory Milestone in Saudi Arabia Cuprina's 49%-owned associate, Cuprina MENA Co. Ltd, has received official product classification from the Saudi Food and Drug Authority (SFDA) for MEDIFLY, the Company's medical-grade maggot debridemen

SINGAPORE, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced its financial results for the six months ended June 30, 2025. "Although our revenue decreased and our net loss increased compared with the same period last year, the first six months of 2025 allowed us to achieve significant advances in both diversifying our product and technology portfolio and expanding our geographic footprint," said Cuprina Chief Executive Officer, Mr. David Quek Yong Qi. Diversification

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today announced it has received a letter of noncompliance from The Nasdaq Stock Market LLC ("Nasdaq"), dated November 26, 2025, notifying the Company that based on Cuprina's closing bid price for the last 30 consecutive business days, the Company no longer meets the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A), th

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical company developing and marketing products for the chronic wounds, infertility, and cosmeceuticals sectors, today said it has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions Pte Ltd (SBS), a treater and disposer of bio-medical waste, to explore the integration of Cuprina's medical waste recycling technology into SBS's existing waste management facility in Singapore. The collaboration aims to develop an integrated process that will further reduce reliance on incineration and landfilling, enhance recycling efficiency, unlock new

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

SINGAPORE, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that the Company's management team, including Chief Executive Officer, David Quek, will present at the Skyline Signature Series™ on Wednesday, October 8th, 2025, at 11:00 AM ET.  This will be a live, interactive online event where investors are invited to ask the Company questions in real-time. All investors must pre-register. Event:Skylin

6-K - Cuprina Holdings (Cayman) LTD (0001995704) (Filer)

Singapore, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("Cuprina" or "the Company") issued the following statement in response to recent unusual trading activity and speculation surrounding the Company. Over the past week, the Company's stock has experienced heightened trading volatility, which we understand has raised concerns among some shareholders. We want to take this opportunity to reaffirm that Cuprina is a fully operational, legally compliant, and mission-driven biotechnology company. We remain focused on advancing our pipeline, expanding access to our biotherapeutic solutions, and delivering long-term value to patients, clinicians, and shareh